Breast cancer study aims to find best Pre-Surgery therapy
NCT ID NCT05621564
First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 3 times
Summary
This study is looking at how different treatments given before surgery (like chemo, radiation, or hormone therapy) affect breast cancer patients' response and long-term survival. Researchers will compare results based on the type of treatment and patient characteristics. The goal is to learn which pre-operative approach works best for different people.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- pre-operative therapy (chemotherapy, radiation, endocrine therapy, targeted therapy, or other anti-tumor drugs)
- What this could lead to
- If successful, this could help doctors choose the best pre-operative treatment for each breast cancer patient, potentially improving survival and response rates.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary by patient group and may not apply to all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 6,032 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Nov 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will be selected from the hospital where they are treated
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female, Aged ≥18 years * Histologically confirmed primary breast cancer * Plan to receive pre-operative therapy * Adequate organ function Exclusion Criteria: * History of neurological or psychological disease, including epilepsy or dementia * Not suitable to participate in this study judged by investigators
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?